加载中
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
常规交易时段
US$0.3958
−US$0.0166 · -4.03%
盘中时间采用ET。市场数据可能有所延迟。
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$0.3958
52周区间
当前US$0.3958
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
58
合理估值
情绪
41
多空交织
风险
84
极高风险
动量
29
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
日内区间
当前US$0.3958
52周区间
当前US$0.3958
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 4.1万 USD | — | 222.5万 USD | 303.1万 USD | 230.6万 USD |
| 毛利 | −4.1万 USD | — | −222.5万 USD | −303.1万 USD | −230.6万 USD |
| 研究与开发 | 151.6万 USD | 841.8万 USD | 3918万 USD | 6394.9万 USD | 5353.9万 USD |
| 销售、一般及管理费用 | 394.8万 USD | 413.5万 USD | 932.1万 USD | 1221万 USD | 1101.7万 USD |
| 营业费用 | 239.1万 USD | 1624.5万 USD | 4850.1万 USD | 7312.8万 USD | 6441.7万 USD |
| 利息收入 | 51.1万 USD | 18.4万 USD | 85万 USD | 68.9万 USD | 36.8万 USD |
| 利息支出 | — | −5000 USD | 131.4万 USD | 335.9万 USD | 1.5万 USD |
| 折旧和摊销 | 4.1万 USD | 82.3万 USD | 222.5万 USD | 303.1万 USD | 230.6万 USD |
| 营业利润 | −243.2万 USD | −1624.5万 USD | −5072.6万 USD | −7615.9万 USD | −6672.3万 USD |
| 净利润 | −192.1万 USD | −1575.2万 USD | −5160.2万 USD | −7752.5万 USD | −6637万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
